Tamoxifen therapy in a murine model of myotubular myopathy
暂无分享,去创建一个
Arun K. Ramani | M. Brudno | J. Dowling | V. Haucke | L. Groom | R. Dirksen | N. Sabha | N. Maani | Faranak Mavandadnejad | G. Russo | K. Rezai | Nadine Eltayeb | Andrea Pang
[1] L. Decosterd,et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy , 2018, Nature Communications.
[2] N. Messaddeq,et al. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] E. Spangenburg,et al. Deletion of estrogen receptor α in skeletal muscle results in impaired contractility in female mice. , 2018, Journal of applied physiology.
[4] Sapana N. Shah,et al. Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy. , 2018, The American journal of pathology.
[5] Francesco Muntoni,et al. Congenital myopathies: disorders of excitation–contraction coupling and muscle contraction , 2018, Nature Reviews Neurology.
[6] I. Sumara,et al. The MTM1–UBQLN2–HSP complex mediates degradation of misfolded intermediate filaments in skeletal muscle , 2018, Nature Cell Biology.
[7] K. Mamchaoui,et al. Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy , 2017, EMBO molecular medicine.
[8] A. Roux,et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation , 2017, The Journal of clinical investigation.
[9] E. Eugster,et al. Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017. , 2017, Pediatric endocrinology reviews : PER.
[10] F. Muntoni,et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches , 2017, Nature Communications.
[11] J. Dowling,et al. A natural history study of X-linked myotubular myopathy , 2017, Neurology.
[12] A. Ishimine,et al. Tamoxifen-induced Lung Injury , 2017, Internal medicine.
[13] A. Michelucci,et al. Estrogens Protect Calsequestrin-1 Knockout Mice from Lethal Hyperthermic Episodes by Reducing Oxidative Stress in Muscle , 2017, Oxidative medicine and cellular longevity.
[14] L. Zambonin,et al. Glycosides from Stevia rebaudiana Bertoni Possess Insulin-Mimetic and Antioxidant Activities in Rat Cardiac Fibroblasts , 2017, Oxidative medicine and cellular longevity.
[15] J. Dowling,et al. A novel intronic mutation in MTM1 detected by RNA analysis in a case of X-linked myotubular myopathy , 2017, Neurology: Genetics.
[16] Shuling Guo,et al. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice , 2017, Nature Communications.
[17] F. Muntoni,et al. Cellular, biochemical and molecular changes in muscles from patients with X-linked myotubular myopathy due to MTM1 mutations , 2016, Human molecular genetics.
[18] A. Thorburn,et al. Therapeutic Targeting of Autophagy☆ , 2016, EBioMedicine.
[19] J. Dowling,et al. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. , 2016, The Journal of clinical investigation.
[20] R. Wassersug,et al. Tamoxifen in men: a review of adverse events , 2016, Andrology.
[21] C. Schwarzer,et al. Restricting calcium currents is required for correct fiber type specification in skeletal muscle , 2016, Development.
[22] A. Hevener,et al. Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females , 2016, Science Translational Medicine.
[23] I. Jourdain,et al. The Exocyst Complex in Health and Disease , 2016, Front. Cell Dev. Biol..
[24] C. Koumenis,et al. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment. , 2016, Cancer research.
[25] M. Marino,et al. Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation , 2016, Scientific Reports.
[26] V. Haucke,et al. Phosphatidylinositol 3‐phosphates—at the interface between cell signalling and membrane traffic , 2016, The EMBO journal.
[27] J. Dowling,et al. Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons , 2016, Journal of neuropathology and experimental neurology.
[28] V. Haucke,et al. A phosphoinositide conversion mechanism for exit from endosomes , 2016, Nature.
[29] A. Hevener,et al. Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome , 2015, Molecular and Cellular Endocrinology.
[30] A. Beggs,et al. Gene replacement rescues severe muscle pathology and prolongs survival in myotubularin-deficient mice and dogs. , 2015, Annals of translational medicine.
[31] S. Hsieh,et al. Dynamin-2 mutations associated with centronuclear myopathy are hypermorphic and lead to T-tubule fragmentation. , 2015, Human molecular genetics.
[32] Frank Noé,et al. Crystal structure of the dynamin tetramer , 2015, Nature.
[33] C. Caldas,et al. Corrigendum: Progesterone receptor modulates ERα action in breast cancer , 2015, Nature.
[34] H. Kuperman,et al. Tamoxifen Improves Final Height Prediction in Girls with McCune-Albright Syndrome: A Long Follow-Up , 2015, Hormone Research in Paediatrics.
[35] E. Zanoteli,et al. DNM2 mutations in a cohort of sporadic patients with centronuclear myopathy , 2015, Genetics and molecular biology.
[36] Jianming Xu,et al. Tamoxifen Inhibits ER-negative Breast Cancer Cell Invasion and Metastasis by Accelerating Twist1 Degradation , 2015, International journal of biological sciences.
[37] P. Bassereau,et al. BIN1/M-Amphiphysin2 induces clustering of phosphoinositides to recruit its downstream partner dynamin , 2014, Nature Communications.
[38] M. Gautel,et al. Pathogenic Mechanisms in Centronuclear Myopathies , 2014, Front. Aging Neurosci..
[39] V. Giguère,et al. Estrogen-related receptor-α coordinates transcriptional programs essential for exercise tolerance and muscle fitness. , 2014, Molecular endocrinology.
[40] T. Baumgart,et al. BIN1 Membrane Curvature Sensing and Generation Show Autoinhibition Regulated by Downstream Ligands and PI(4,5)P2 , 2014, Biochemistry.
[41] S. Bodine,et al. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. , 2014, American journal of physiology. Endocrinology and metabolism.
[42] J. Dowling,et al. Triadopathies: An Emerging Class of Skeletal Muscle Diseases , 2014, Neurotherapeutics.
[43] Stephen C Martinkovich,et al. Selective estrogen receptor modulators: tissue specificity and clinical utility , 2014, Clinical interventions in aging.
[44] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[45] B. Picard,et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways , 2014, Cellular and Molecular Life Sciences.
[46] D. Drubin,et al. Actin and dynamin2 dynamics and interplay during clathrin-mediated endocytosis , 2014, The Journal of cell biology.
[47] E. Levin,et al. Membrane-localized estrogen receptor α is required for normal organ development and function. , 2014, Developmental cell.
[48] S. Khosla,et al. Dissection of Estrogen Receptor Alpha Signaling Pathways in Osteoblasts Using RNA-Sequencing , 2014, PloS one.
[49] N. Romero,et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. , 2014, The Journal of clinical investigation.
[50] E. McNally,et al. Dynamin 2 the rescue for centronuclear myopathy. , 2014, The Journal of clinical investigation.
[51] Susan C. Brown,et al. Adenovirus-mediated expression of myogenic differentiation factor 1 (MyoD) in equine and human dermal fibroblasts enables their conversion to caffeine-sensitive myotubes , 2014, Neuromuscular Disorders.
[52] I. Barone,et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines , 2014, Breast Cancer Research.
[53] R. Main,et al. Female Mice Lacking Estrogen Receptor‐Alpha in Osteoblasts Have Compromised Bone Mass and Strength , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[54] N. Hah,et al. Hormone-regulated transcriptomes: Lessons learned from estrogen signaling pathways in breast cancer cells , 2014, Molecular and Cellular Endocrinology.
[55] C. Caputo,et al. The excitation–contraction coupling mechanism in skeletal muscle , 2014, Biophysical Reviews.
[56] R. Grange,et al. Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy , 2014, Science Translational Medicine.
[57] Weizhu Wu,et al. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors , 2014, Journal of Translational Medicine.
[58] H. Billig,et al. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. , 2014, American journal of translational research.
[59] T. Kunoh,et al. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. , 2014, European journal of medicinal chemistry.
[60] M. Egerman,et al. Signaling pathways controlling skeletal muscle mass , 2013, Critical reviews in biochemistry and molecular biology.
[61] J. Laporte,et al. The myotubularin–amphiphysin 2 complex in membrane tubulation and centronuclear myopathies , 2013, EMBO reports.
[62] J. Mandel,et al. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin‐proteasome pathways , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[63] N. Romero,et al. Extensive morphological and immunohistochemical characterization in myotubular myopathy , 2013, Brain and behavior.
[64] P. Vanhoutte,et al. Differential Ligand Binding Affinities of Human Estrogen Receptor-α Isoforms , 2013, PloS one.
[65] B. Payrastre,et al. Myotubularin and PtdIns3P remodel the sarcoplasmic reticulum in muscle in vivo , 2013, Journal of Cell Science.
[66] R. Grange,et al. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. , 2013, Human molecular genetics.
[67] A. Kaminska,et al. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy , 2013, Neuromuscular Disorders.
[68] L. Decosterd,et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. , 2013, The American journal of pathology.
[69] A. Brunello,et al. Treatment of estrogen receptor-positive breast cancer. , 2013, Current medicinal chemistry.
[70] K. Petersen,et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. , 2013, Endocrinology.
[71] A. Goldberg. Development of proteasome inhibitors as research tools and cancer drugs , 2012, The Journal of cell biology.
[72] Jeffrey A. Porter,et al. Defective Autophagy and mTORC1 Signaling in Myotubularin Null Mice , 2012, Molecular and Cellular Biology.
[73] B. Klaholz,et al. Phosphatase-Dead Myotubularin Ameliorates X-Linked Centronuclear Myopathy Phenotypes in Mice , 2012, PLoS genetics.
[74] J. Dowling,et al. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models , 2012, Disease Models & Mechanisms.
[75] Min Jae Lee,et al. Emerging roles of the ubiquitin-proteasome system in the steroid receptor signaling , 2012, Archives of pharmacal research.
[76] J. Laporte,et al. Myotubularins and associated neuromuscular diseases , 2012 .
[77] U. Suter,et al. Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination. , 2012, Brain : a journal of neurology.
[78] J. Dowling,et al. Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype. , 2012, Human molecular genetics.
[79] H. Goebel,et al. Protein aggregation in congenital myopathies. , 2011, Seminars in pediatric neurology.
[80] Christos C. Petrou,et al. Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β , 2011, Steroids.
[81] B. Al-Ayadhy,et al. Analysis of estrogen receptor isoforms and variants in breast cancer cell lines. , 2011, Experimental and therapeutic medicine.
[82] Jeroen F. J. Laros,et al. LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.
[83] J. Hartwig,et al. Direct dynamin–actin interactions regulate the actin cytoskeleton , 2010, The EMBO journal.
[84] A. Kiger,et al. Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions , 2010, The Journal of cell biology.
[85] D. Price,et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism , 2010, Proceedings of the National Academy of Sciences.
[86] R. Karas,et al. Rapid progress for non-nuclear estrogen receptor signaling. , 2010, The Journal of clinical investigation.
[87] P. Novick,et al. Phosphatidylinositol 4-phosphate controls both membrane recruitment and a regulatory switch of the Rab GEF Sec2p. , 2010, Developmental cell.
[88] Gordon L. Warren,et al. Estrogen Regulates Estrogen Receptors and Antioxidant Gene Expression in Mouse Skeletal Muscle , 2010, PloS one.
[89] Roger E. Taylor,et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma , 2010, Journal of Neuro-Oncology.
[90] N. Mizushima,et al. Methods in Mammalian Autophagy Research , 2010, Cell.
[91] Matthew D. Young,et al. Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.
[92] A. Hevener,et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. , 2010, American journal of physiology. Endocrinology and metabolism.
[93] Davis J. McCarthy,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[94] A. Buj-Bello,et al. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase , 2009, Proceedings of the National Academy of Sciences.
[95] Adrian V. Lee,et al. Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer , 2009, Oncogene.
[96] C. Dieli-Conwright,et al. Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells , 2009, Acta physiologica.
[97] F. Muntoni,et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies , 2009, Neuromuscular Disorders.
[98] Andrew P. Vreede,et al. Loss of Myotubularin Function Results in T-Tubule Disorganization in Zebrafish and Human Myotubular Myopathy , 2009, PLoS genetics.
[99] M. Esbjörnsson,et al. Expression of both oestrogen receptor alpha and beta in human skeletal muscle tissue , 2009, Histochemistry and Cell Biology.
[100] Eun-Chang Lee,et al. Tamoxifen Suppresses Clusterin Level through Akt Inactivation and Proteasome Degradation in Human Prostate Cancer Cells , 2009 .
[101] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[102] H. Chao,et al. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. , 2008, Taiwanese journal of obstetrics & gynecology.
[103] Jang-Yang Chang,et al. Tamoxifen accelerates proteasomal degradation of O6‐methylguanine DNA methyltransferase in human cancer cells , 2007, International journal of cancer.
[104] C. Wallgren‐Pettersson,et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy , 2007, Nature Genetics.
[105] S. Tapscott,et al. Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination , 2007, The Journal of cell biology.
[106] M. Brielmeier,et al. Optimization of spatiotemporal gene inactivation in mouse heart by oral application of tamoxifen citrate , 2007, Genesis.
[107] Chin-Yo Lin,et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.
[108] Yosuke Nagata,et al. Pax7 and myogenic progression in skeletal muscle satellite cells , 2006, Journal of Cell Science.
[109] I. Nishino,et al. Gene expression analyses in X-linked myotubular myopathy , 2005, Neurology.
[110] Maria Sjöberg,et al. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.
[111] G. Leclercq,et al. Role of the proteasome in the regulation of estrogen receptor α turnover and function in MCF-7 breast carcinoma cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[112] P. Visca,et al. S-palmitoylation modulates human estrogen receptor-α functions , 2004 .
[113] M. Krawczak,et al. Genotype–phenotype correlations in X-linked myotubular myopathy , 2002, Neuromuscular Disorders.
[114] D. Shapiro,et al. Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death* , 2002, The Journal of Biological Chemistry.
[115] Hala G. Zahreddine,et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[116] A. Howell,et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] J. Vonesch,et al. The PtdIns3P phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane ruffles. , 2002, Journal of cell science.
[118] K. Patel,et al. Muscle development genes: their relevance in neuromuscular disorders , 2002, Neuromuscular Disorders.
[119] G. Iwamoto,et al. Increased adipose tissue in male and female estrogen receptor-α knockout mice , 2000 .
[120] C. Wallgren‐Pettersson,et al. MTM1 mutations in X‐linked myotubular myopathy , 2000, Human mutation.
[121] R. Clarke,et al. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[122] T Reilly,et al. Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. , 1999, Clinical science.
[123] B. O’Malley,et al. Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[124] S. Jukić,et al. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. , 1999, Gynecologic oncology.
[125] Wei Zhao,et al. Medical complications in long-term survivors with X-linked myotubular myopathy. , 1999, The Journal of pediatrics.
[126] A. Fattorossi,et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines , 1999, British Journal of Cancer.
[127] W. Bursch,et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. , 1996, Carcinogenesis.
[128] S. Klauck,et al. A gene mutated in X–linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast , 1996, Nature Genetics.
[129] M. Karasek,et al. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin , 1995, In Vitro Cellular & Developmental Biology - Animal.
[130] N. Webster,et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.
[131] T. Munsat,et al. Centronuclear ("myotubular") myopathy. , 1969, Archives of neurology.
[132] S. Friant,et al. WANTED - Dead or alive: Myotubularins, a large disease-associated protein family. , 2017, Advances in biological regulation.
[133] H. Hwang,et al. Drug affinity responsive target stability (DARTS) for small-molecule target identification. , 2015, Methods in molecular biology.
[134] R. Vohra,et al. Dysferlin and myoferlin regulate transverse tubule formation and glycerol sensitivity. , 2014, The American journal of pathology.
[135] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[136] I. Nishino,et al. Molecular Pathogenesis of Genetic and Inherited Diseases Increased Expression of Wild-Type or a Centronuclear Myopathy Mutant of Dynamin 2 in Skeletal Muscle of Adult Mice Leads to Structural Defects and Muscle Weakness , 2011 .
[138] P. Tiidus,et al. The Influence of Estrogen on Skeletal Muscle , 2010, Sports medicine.
[139] A. Beggs,et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. , 2005, Nature genetics.
[140] M. McNiven,et al. Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion. , 2004, Nature cell biology.
[141] E. Lam,et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. , 2003, Oncogene.
[142] R. Woledge,et al. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. , 1993, Clinical science.
[143] P. D. White. The long follow-up. , 1956, Journal of chronic diseases.